The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.


This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
01 August 2022

Darnitsa released 8 new medicines in the first half of 2022

01 August 2022

Despite the war, the pharmaceutical company "Darnitsa" continues to create new medicines. During the first half of 2022, the company released 8 new products at one time, including 7 medicines: Perindopres Trio for blood pressure control, analgesics Dexpro and Pregabalin-Darnitsa, anti-radiation medicine Kalii Iodidum-125-Darnitsa, mucolytic drugs as granules (Dvatse 100, Dvatse 200 and Dvatse 200 Hot drink) and hygienic product Pantestin Darnitsa for burns and cuts healing. *

In July, another 2 new medicines in the DVATSE family (Dvatse Long and Dvatse Long Hot Drink) entered the market. DVATSE is a drug used for the treatment of acute and chronic diseases of the bronchopulmonary system.

DVATSE is indicated for acute and chronic diseases of the bronchopulmonary system accompanied by increased production of sputum. Acetylcysteine in the formulation facilitates the discharge of sputum. In addition, acetylcysteine promotes the synthesis of glutathione, which is an important detoxification factor. This feature of acetylcysteine, in particular in the composition of DVATSE 200 and DVATSE LONG, makes it possible to use these drugs as an antidote for acute paracetamol overdose.

Last year, Darnitsa launched DVATSE as effervescent tablet formulation**. The drug was developed as a result of international cooperation with a European manufacturer who specializes in the development of granules for oral solutions, effervescent granules and tablets, as well as orodispersible tablets.

This year, 5 new DVATSE medicines are Darnitsa's own development formulated as granules and a hot drink. ***

"For Darnitsa as the leader of the domestic pharmaceutical market****, it is extremely important to continue its activities in full. Since the beginning of the full-scale military invasion of the Russian Federation on the territory of Ukraine, we have not stopped production for a single day and, since April, we have reached pre-war production levels. We also continue to develop and to launch new medicines in accordance with our pre-war plan. It is critically important for Ukrainian businesses to work on the economic front, pay taxes, and provide jobs. The development of one's own drugs from a domestic pharmaceutical company is also an important component of the national security, because in critical moments faced by our country, the lack of supplies from abroad can cause a shortage of necessary medicines," said Inna Deniak, Director of Business Development in the Pharmaceutical Company Darnitsa.


PJSC Pharmaceutical Company Darnitsa was founded in 1930. Since 1998, Darnitsa has been the leader in Ukraine as for drug production in physical terms. Strategic areas of products portfolio development include cardiology, neurology, and pain management. During the war, Darnitsa has passed 1.5 million packages of medicines at a cost of UAH 132 million for charitable uses to MOH, Ukrainian Armed Forces, hospitals and charity organisations

* Marketing Authorization for Perindopres Trio MA No. UA/19239/01/04, UA/19239/01/03, UA/19239/01/02, UA/19239/01/01, Dexpro MA No. UA/17373/02/01, Pregabalin-Darnitsa MA No. UA/16414/01/03, Kalii Iodidum-125-Darnitsa MA No. UA/19348/01/01. Be sure to read the instructions before taking.

Pantestin Darnitsa® TU U 20.4-00481212-002:2021

** The medicine is available without a prescription and is recommended for use in children over 2 years of age. Marketing Authorization for Dvatse 200 No. UA/18138/01/01, Dvatse Long No. UA/18139/01/01.

*** The medicine is available without a prescription and is recommended for use in children over 12 years of age. Marketing Authorization for Dvatse 100 (granules) No. UA/19247/01/01, Dvatse 200 (granules) No. UA/19247/01/02, Dvatse Long (granyles) No. UA/19310/01/01, Dvatse 200 Hot Drink No. UA/19261/01/01, Dvatse Long Hot Drink No. UA/19262/01/01.

**** In physical terms according to Proxima Research

The information must be exclusively distributed in specialized publications intended for medical institutions and doctors

1 / 1

Recommended drugs

Specialized edition for medical institutions and doctors.